US › Healthcare

Evolus Inc (EOLS)

US · Healthcare · Drug Manufacturers - Specialty & Generic

$8.01+0.25%

Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue

$84.1M

Revenue YoY

+21.2%

Net profit

$-8.1M

EPS

$-0.09

EPS estimate

$-0.09

Net margin

-9.6%

EPS came in at -0.09 against a street estimate of -0.09 — a beat of 0.0%.

Key statistics

Market cap

$527.7M

Forward P/E

16.8

P/B

53.71

Book value

$-0.47

EPS (TTM)

$-0.54

52-week high

$9.31

52-week low

$3.86

50-day MA

$7.41

200-day MA

$6.10

Beta

1.43

Analyst view

Analysts rate Evolus Inc a strong buy (7 buy, 0 hold, 0 sell out of 7) with an average price target of $15.00.

Shareholding

Insiders

14.48%

Institutions

77.75%

Largest institutional holders

Fund	Stake
Nantahala Capital Management, LLC	9.65%
BlackRock Inc	6.50%
BRAIDWELL LP	4.70%
Frazier Life Sciences Management, L.P.	3.98%
Vanguard Capital Management, LLC	3.74%
Millennium Management LLC	2.71%
Stonepine Capital Management Llc	2.66%
Pinnacle Associates Inc	2.25%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Evolus Inc — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Novo Nordisk A/S Gilead Sciences Inc Abbott Laboratories

Data updated 2026-09-18.